Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gulf Pharmaceutical Industries PSC Total Current Liabilities Chart
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.
Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.
What does a Total Current Liabilities of د.إ549 Mil mean?
Gulf Pharmaceutical Industries PSC (ADX:JULPHAR) has a Total Current Liabilities of د.إ549 Mil as of Mar. 2026. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Gulf Pharmaceutical Industries PSC and its competitors.
Is Gulf Pharmaceutical Industries PSC's Total Current Liabilities too high?
Gulf Pharmaceutical Industries PSC's current Total Current Liabilities is د.إ549 Mil. Overall, Gulf Pharmaceutical Industries PSC has a GF Score™ of 54/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Gulf Pharmaceutical Industries PSC's Total Current Liabilities compare to MCK and COR?
Gulf Pharmaceutical Industries PSC's Total Current Liabilities of د.إ549 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Liabilities for a Medical Distribution company?
A good Total Current Liabilities depends on the Medical Distribution industry context. However, Total Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Liabilities mean?
A high Total Current Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Gulf Pharmaceutical Industries PSC and its competitors. Gulf Pharmaceutical Industries PSC's current Total Current Liabilities is د.إ549 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gulf Pharmaceutical Industries PSC stock overvalued right now?
Based on GuruFocus' analysis, Gulf Pharmaceutical Industries PSC (ADX:JULPHAR) is currently considered Fairly Valued. The stock's GF Value™ is د.إ1.08, compared to a current price of د.إ1.05 — trading 2.8% below its estimated fair value. The current Total Current Liabilities is د.إ549 Mil. Gulf Pharmaceutical Industries PSC's overall GF Score™ is 54/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Liabilities calculated?
Total Current Liabilities is calculated from a company's financial statements. For Gulf Pharmaceutical Industries PSC (ADX:JULPHAR), the current Total Current Liabilities is د.إ549 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gulf Pharmaceutical Industries PSC (ADX:JULPHAR) Overvalued in 2026?
Based on GuruFocus' analysis, Gulf Pharmaceutical Industries PSC stock appears to be undervalued.
The current stock price of د.إ1.05 is trading 2.8% below its estimated GF Value™ of د.إ1.08.
GuruFocus considers Gulf Pharmaceutical Industries PSC to be Fairly Valued.
Key valuation signals for ADX:JULPHAR:
Total Current Liabilities: د.إ549 Mil
GF Value™: د.إ1.08 vs. price of د.إ1.05 (2.8% below fair value)
No single metric tells the full story. See the ADX:JULPHAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gulf Pharmaceutical Industries PSC Business Description
Gulf Pharmaceutical Industries PSC is in the business of manufacturing and selling medicines, drugs, and various other types of pharmaceutical and medical compounds in addition to cosmetic compounds. The company operates in four segments: Manufacturing, Trading, Investments, and others. The majority of its revenue is generated from the Manufacturing segment. The geographical segments are UAE, Other GCC countries, and Other countries. It derives maximum revenue from UAE. Its business is centered around General Medicines in the retail pharmacy channel and hospitals as well as speciality Products. Its medicines also targets therapeutic segments such as Diabetes, Gastrointestinal Tract (GIT), Respiratory, Wounds and Scars, Anti-infectives, Anemia, Gynecology, Erectile Dysfunction and Others.
54GF Score
Get the complete analysis for ADX:JULPHAR
Total Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADX:JULPHAR has been successfully added to your 
